Space Drug Development
Merck's Keytruda, a $25 billion monoclonal antibody, faces challenges in dosing due to inconsistent crystal sizes formed on Earth. However, experiments on the International Space Station reveal that microgravity allows for the creation of uniform crystals, potentially leading to more precise dosing and easier administration for patients. This innovative approach could revolutionize how biologics are manufactured and delivered.In this clip
From this podcast
Newcomer Podcast
Spaceman Explains to Earthman How Things Work (with Delian Asparouhov)
Related Questions